Table 6.
Association of various non-DIPSS factors with outcome after adjustment for DIPSS
| HSCT outcome | HR | 95% CI | P |
|---|---|---|---|
| Overall mortality | |||
| Alternative donor* | 1 | ||
| HLA-matched related | 0.65 | 0.40-1.06 | .08 |
| Other conditioning* | 1 | ||
| High-dose conditioning† | 0.69 | 0.34-1.41 | .31 |
| HCT-CI | .13 | ||
| PBSC* | 1 | ||
| Bone marrow | 1.42 | 0.85-2.39 | .18 |
| JAK2 wild-type | 1 | ||
| JAK2-V617F mutant | 0.76 | 0.36-1.57 | .45 |
| No splenectomy* | 1 | ||
| Splenectomy | 0.51 | 0.26-1.00 | .05 |
| Relapse or death | |||
| Alternative donor* | 1 | ||
| HLA-matched related | 0.70 | 0.44-1.12 | .13 |
| Other conditioning* | 1 | ||
| High-dose conditioning† | 0.73 | 0.36-1.49 | .39 |
| HCT-CI | .24 | ||
| PBSC* | 1 | ||
| Bone marrow | 1.47 | 0.89-2.45 | .14 |
| JAK2 wild-type | 1 | ||
| JAK2-V617F mutant | 0.92 | 0.46-1.82 | .80 |
| No splenectomy* | 1 | ||
| Splenectomy | 0.74 | 0.41-1.33 | .32 |
| Relapse | |||
| Alternative donor* | 1 | ||
| HLA-matched related | 0.73 | 0.28-1.86 | .50 |
| Other conditioning* | 1 | ||
| High-dose conditioning† | 1.43 | 0.18-11.02 | .73 |
| HCT-CI | .46 | ||
| PBSC* | 1 | ||
| Bone marrow | 1.52 | 0.57-4.04 | .40 |
| JAK2 wild-type | 1 | ||
| JAK2-V617F mutant | 2.16 | 0.54-8.65 | .28 |
| No splenectomy* | 1 | ||
| Splenectomy | 1.24 | 0.46-3.31 | .67 |
| NRM | |||
| Alternative donor* | 1 | ||
| HLA-matched related | 0.69 | 0.40-1.18 | .18 |
| Other conditioning* | 1 | ||
| High-dose conditioning† | 0.65 | 0.30-1.38 | .26 |
| HCT-CI | .08 | ||
| PBSC* | 1 | ||
| Bone marrow | 1.45 | 0.80-1.63 | .23 |
| JAK2 wild-type | 1 | ||
| JAK2-V617F mutant | 0.67 | 0.29-1.52 | .33 |
| No splenectomy* | 1 | ||
| Splenectomy | 0.57 | 0.27-1.22 | .15 |
*
Referent category. HCT-CI was treated as a continuous variable.
†
Indicates BU, 16 mg/kg oral or intravenous equivalent; TBI, ≥ 12 Gy; treosulfan, 42 g/m2; and I-131–based conditioning.